Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00507-0/fulltext?dgcid=hubspot_email_conferencealerts_acc25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8F11N-uuG_AhdI_PbgjjX9HuExNUuUYK8uI4B7lC2j1ONT4RRc_Y_LYg6A-nY6a8o08ESrHcEEQkwDpYpKwyVppY_5kg&_hsmi=354063385&utm_content=354063385&utm_source=hs_email